Patent US2817918A successfully refreshed from Google Patents.
Patent US4317832A successfully refreshed from Google Patents.
US4317832A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Indolyl and methylindolyl substituted aminoalkyl guanidines
Assignee: Individual
•
Filing: 1979-09-05
•
Granted: 1982-03-02
•
Expires: 1999-09-05
Abstract
Abstract Compounds corresponding to the formula <IMAGE> I are disclosed, wherein Alk represents a C2-C5-alkylene groups optionally substituted by a hydroxy group and Ar represent an optionally substituted phenyl, naphthyl, tetrahydronaphthyl, indanyl or indenyl radical or a monocyclic or condensed bicyclic or tricyclic heterocyclic radical which is optionally substituted, the heterocyclic radical consisting of individual rings having 5 or 6 members and optionally containing from 1 to 4 hetero atoms, and the acid addition salts thereof. A process for producing these compounds is also disclosed. These substituted aminoalkyl guanidines block the beta -receptors of the adrenergic nerve system, and also reduce blood pressure.
Inventors
- 👤 Karl-Heinz Klingler
- 👤 Axel Kleemann
- 👤 Fritz Stroman
- 👤 Klaus Thiemer
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 10:36
CPC Classifications
C; C07; C07D; C07D209/00; C07D209/02; C07D209/04; C07D209/08; A; A61; A61P; A61P25/00; A61P25/02; A61P27/00; A61P27/02; C07C; C07C279/00; C07C279/04; C07C279/12; C07D209/56; C07D209/80; C07D209/82; C07D209/88
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
44 words
A substituted aminoalkyl guanidine corresponding to the following formula: ##STR35## wherein Alk represents a C 2 -C 5 -alkylene group or such a group substituted by a hydroxy group and Ar represents indolyl and methyl indolyl or a pharmaceutically acceptable acid addition salt thereof.
Claim 2
Dependent Claim
44 words
A substituted aminoalkyl guanidine corresponding to the following formula: ##STR35## wherein Alk represents a C 2 -C 5 -alkylene group or such a group substituted by a hydroxy group and Ar represents indolyl and methyl indolyl or a pharmaceutically acceptable acid addition salt thereof.
Claim 3
Dependent Claim
11 words
A compound according to claim 1 wherein Ar is indolyl-(4)-or 2-methylindolyl-(4)-.
Claim 4
Dependent Claim
11 words
A compound according to claim 2 wherein Ar is 2-methyl indolyl-(4)-.
Claim 5
Dependent Claim
10 words
A compound according to claim 3 which is 3-{-[2-methyl-indolyl-(4)-oxy]-2-hydroxypropylamino}-butyl guanidine.
Claim 6
Dependent Claim
10 words
A compound according to claim 3 which is 3-{3-[2-methyl-indolyl-(4)-oxy]-2-hydroxypropylamino}-propyl guanidine.
Claim 7
Dependent Claim
10 words
A compound according to claim 2 which is 3-{3-[indolyl-(4)-oxy]-2-hydroxypropyl-amine}-propyl guanidine.
Claim 8
Dependent Claim
33 words
A medicament suitable for blocking of β-receptors of the adrenergic nerve system which comprises at least one substituted aminoalkyl guanidine as claimed in claim 1, together with at least one pharmacologically acceptable carrier.
Claim 9
Dependent Claim
37 words
A method of blocking the β-receptors of the adrenergic nerve system in a mammal comprising administering to the mammal an effective amount of a compound of claim 1 to block the β-receptors of the adrenergic nerve system.
Claim 10
Dependent Claim
12 words
A method according to claim 8 wherein the compound is administered orally.
Claim 11
Dependent Claim
12 words
A method according to claim 8 wherein the compound is administered intravenously.
Claim 12
Dependent Claim
11 words
A method according to claim 8 wherein Ar is 2-methyl indolyl-(4).
Claim 13
Dependent Claim
12 words
A method according to claim 11 wherein the compound is 3-{3-[2-methyl-indolyl-(4)-oxy]-2-hydroxypropylamino}-butyl guanidine.
Claim 14
Dependent Claim
12 words
A method according to claim 11 wherein the compound is 3-{3-[2-methyl-indolyl-(4)-oxy]-2-hydroxypropylamino}-propyl guanidine.
Claim 15
Dependent Claim
12 words
A method according to claim 11 wherein the compound is 3-{3-[indolyl-(4)-oxy]-2-hydroxypropylamino}-propyl guanidine.
References Cited (Backward Citations)
FR778027A
Cited
US3317570A
Cited
US3501497A
Cited
US3471515A
Cited
US3499003A
Cited
US3644353A
Cited
US3542873A
Cited
US3821301A
Cited
GB1398918A
Cited
US4144340A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-03-01 | 1985-08-31 | 1986-03-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-03-01 | 1989-08-31 | 1990-03-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-03-01 | 1993-08-31 | 1994-03-02 | $7700.00 | Window Closed / Lapsed |